Free Trial
$100 Off Ends Tonight! MarketBeat All Access Returns to $249
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Save $100 Now
Claim MarketBeat All Access Sale Promotion

Catalyst Pharmaceuticals (CPRX) Financials

Catalyst Pharmaceuticals logo
$31.26 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$31.22 -0.04 (-0.11%)
As of 05/22/2026 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Catalyst Pharmaceuticals

Annual Income Statements for Catalyst Pharmaceuticals

This table shows Catalyst Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -20 -18 -18 -34 32 75 39 83 71 164 214
Consolidated Net Income / (Loss)		 -20 -18 -18 -34 32 75 39 83 71 164 214
Net Income / (Loss) Continuing Operations		 -20 -18 -18 -34 32 75 39 83 71 164 214
Total Pre-Tax Income 		-20 -18 -18 -34 33 42 53 105 95 216 284
Total Operating Income		 -20 -19 -19 -35 32 41 52 102 87 195 258
Total Gross Profit		 0.00 0.00 0.00 0.50 88 102 119 180 346 423 502
Total Revenue		 0.00 0.00 0.00 0.50 102 119 141 214 398 492 589
Operating Revenue		 0.00 0.00 0.00 0.50 102 119 141 214 398 492 589
Total Cost of Revenue		 0.00 0.00 0.00 0.00 15 17 22 34 52 69 87
Operating Cost of Revenue		 - - - 0.00 15 17 22 34 52 69 87
Total Operating Expenses		 20 19 19 36 56 61 67 78 259 228 244
Selling, General & Admin Expense		 8.60 7.91 7.30 16 37 44 50 57 134 178 194
Research & Development Expense		 12 11 11 20 19 16 17 20 93 13 13
Amortization Expense		 - - - - - - 0.00 1.10 33 37 37
Total Other Income / (Expense), net		 0.17 1.21 0.27 1.29 1.59 0.59 0.28 2.88 7.70 21 26
Other Income / (Expense), net		 0.17 1.21 0.27 1.29 1.59 0.59 0.28 2.88 7.70 21 26
Income Tax Expense		 0.00 0.00 0.00 0.00 1.53 -33 13 22 23 52 69
Basic Earnings per Share		 ($0.25) ($0.22) ($0.21) ($0.33) $0.31 $0.72 $0.38 $0.80 $0.67 $1.38 $1.75
Weighted Average Basic Shares Outstanding		 80.86M 82.88M 85.80M 102.63M 102.94M 103.51M 103.38M 103.37M 106.28M 118.46M 122.29M
Diluted Earnings per Share		 ($0.25) ($0.22) ($0.21) ($0.33) $0.30 $0.71 $0.37 $0.75 $0.63 $1.31 $1.68
Weighted Average Diluted Shares Outstanding		 80.86M 82.88M 85.80M 102.63M 106.02M 106.24M 107.80M 111.38M 113.75M 124.94M 127.26M
Weighted Average Basic & Diluted Shares Outstanding		 80.86M 82.88M 85.80M 102.63M 103.41M 103.82M 102.74M 105.65M 117.86M 121.45M 122.12M

Quarterly Income Statements for Catalyst Pharmaceuticals

This table shows Catalyst Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -31 35 23 41 44 56 57 52 53 53 64
Consolidated Net Income / (Loss)		 -31 35 23 41 44 56 57 52 53 53 64
Net Income / (Loss) Continuing Operations		 -31 35 23 41 44 56 57 52 53 53 64
Total Pre-Tax Income 		-38 47 29 56 57 74 71 69 71 72 84
Total Operating Income		 -37 42 27 54 51 63 63 66 66 62 73
Total Gross Profit		 89 95 86 107 109 120 124 126 126 127 135
Total Revenue		 103 111 99 123 129 142 141 147 148 153 149
Operating Revenue		 103 111 99 123 129 142 141 147 148 153 149
Total Cost of Revenue		 14 16 13 15 19 22 18 21 23 26 14
Operating Cost of Revenue		 14 16 13 15 19 22 18 21 23 26 14
Total Operating Expenses		 126 53 59 53 59 57 60 60 59 65 62
Selling, General & Admin Expense		 34 42 47 41 46 44 47 46 47 53 49
Research & Development Expense		 84 1.97 2.58 2.99 3.28 3.80 3.89 4.36 2.66 1.81 2.66
Amortization Expense		 8.49 9.06 9.34 9.34 9.35 9.34 9.35 9.34 9.34 9.47 9.70
Total Other Income / (Expense), net		 -0.83 5.02 1.96 1.54 6.30 11 7.92 3.00 4.77 10 11
Other Income / (Expense), net		 -0.83 5.02 1.96 1.54 6.30 11 7.92 3.00 4.77 10 11
Income Tax Expense		 -7.26 12 5.81 15 13 18 15 17 18 19 20
Basic Earnings per Share		 ($0.29) $0.32 $0.20 $0.35 $0.37 $0.46 $0.47 $0.43 $0.43 $0.42 $0.52
Weighted Average Basic Shares Outstanding		 106.57M 106.28M 116.81M 118.18M 118.93M 118.46M 121.47M 122.16M 122.60M 122.29M 122.25M
Diluted Earnings per Share		 ($0.29) $0.33 $0.19 $0.33 $0.35 $0.44 $0.45 $0.41 $0.42 $0.40 $0.50
Weighted Average Diluted Shares Outstanding		 106.57M 113.75M 123.40M 124.66M 125.41M 124.94M 126.96M 127.54M 127.09M 127.26M 126.90M
Weighted Average Basic & Diluted Shares Outstanding		 106.61M 117.86M 118.12M 118.69M 119.27M 121.45M 121.98M 122.39M 122.91M 122.12M 122.38M

Annual Cash Flow Statements for Catalyst Pharmaceuticals

This table details how cash moves in and out of Catalyst Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 19 -14 44 -41 73 41 41 127 -161 380 192
Net Cash From Operating Activities		 -18 -18 -14 -26 35 45 60 116 144 240 209
Net Cash From Continuing Operating Activities		 -18 -18 -14 -26 35 45 60 116 144 240 209
Net Income / (Loss) Continuing Operations		 -20 -18 -18 -34 32 75 39 83 71 164 214
Consolidated Net Income / (Loss)		 -20 -18 -18 -34 32 75 39 83 71 164 214
Depreciation Expense		 0.03 0.04 0.05 0.04 0.06 0.09 0.19 0.14 0.32 0.40 0.38
Amortization Expense		 - - - 0.00 0.24 0.00 0.00 1.10 33 37 37
Non-Cash Adjustments To Reconcile Net Income		 1.52 0.95 2.59 3.11 3.26 6.12 7.22 13 94 16 24
Changes in Operating Assets and Liabilities, net		 0.66 -0.88 2.03 4.71 -0.82 -36 13 19 -55 22 -67
Net Cash From Investing Activities		 -0.01 3.55 -0.00 -15 37 -5.01 -11 9.21 -294 -0.56 -0.06
Net Cash From Continuing Investing Activities		 -0.01 3.55 -0.00 -15 37 -5.01 -11 9.21 -294 -0.56 -0.06
Purchase of Property, Plant & Equipment		 -0.02 -0.10 - -0.09 -0.02 -0.01 -1.02 -0.03 -0.23 -0.56 -0.06
Acquisitions		 - - - - - - 0.00 -10 -280 0.00 0.00
Sale and/or Maturity of Investments		 0.02 - - 22 72 5.00 0.00 19 0.00 0.00 0.00
Other Investing Activities, net		 -0.00 3.72 - - - 0.00 0.00 0.00 - 0.00 0.00
Net Cash From Financing Activities		 37 0.07 57 0.29 1.12 0.70 -8.14 1.69 -11 141 -17
Net Cash From Continuing Financing Activities		 37 0.07 57 0.29 1.12 0.70 -8.14 1.69 -11 141 -17
Repurchase of Common Equity		 - - - - 0.00 0.00 -12 -6.91 0.00 -0.30 -25
Issuance of Common Equity		 35 - 54 - - - - 0.00 0.00 141 0.00
Other Financing Activities, net		 2.29 0.07 3.58 0.29 1.12 0.70 3.95 8.60 -11 -0.04 8.31
Cash Interest Paid		 - - - - - - 0.00 0.00 0.71 1.40 0.47
Cash Income Taxes Paid		 - - - 0.00 0.00 2.79 3.00 7.67 50 68 72

Quarterly Cash Flow Statements for Catalyst Pharmaceuticals

This table details how cash moves in and out of Catalyst Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -58 17 173 65 67 75 63 72 37 19 47
Net Cash From Operating Activities		 45 56 32 64 73 71 60 71 32 45 60
Net Cash From Continuing Operating Activities		 45 56 32 64 73 71 60 71 32 45 60
Net Income / (Loss) Continuing Operations		 -31 35 23 41 44 56 57 52 53 53 64
Consolidated Net Income / (Loss)		 -31 35 23 41 44 56 57 52 53 53 64
Depreciation Expense		 0.08 0.08 0.09 0.09 0.11 0.11 0.12 0.12 0.07 0.07 0.07
Amortization Expense		 8.49 9.06 9.34 9.34 9.35 9.34 9.35 9.34 9.34 9.47 9.70
Non-Cash Adjustments To Reconcile Net Income		 85 3.04 9.52 6.78 1.56 -1.61 3.12 11 7.34 2.23 1.35
Changes in Operating Assets and Liabilities, net		 -17 8.62 -10 7.13 18 7.10 -9.28 -1.39 -37 -20 -15
Net Cash From Investing Activities		 -93 -38 -0.20 -0.01 -0.26 -0.09 0.00 -0.03 - -0.03 -0.03
Net Cash From Continuing Investing Activities		 -93 -38 -0.20 -0.01 -0.26 -0.09 0.00 -0.03 - -0.03 -0.03
Purchase of Property, Plant & Equipment		 -0.06 -0.09 -0.20 -0.01 -0.26 -0.09 0.00 -0.03 - -0.03 -0.03
Acquisitions		 -79 -38 0.00 - - - 0.00 - - - 0.00
Purchase of Investments		 - - - - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 -10 -0.67 141 1.16 -5.97 4.43 3.06 0.87 4.65 -26 -13
Net Cash From Continuing Financing Activities		 -10 -0.67 141 1.16 -5.97 4.43 3.06 0.87 4.65 -26 -13
Repurchase of Common Equity		 - - -0.30 - - - 0.00 - - -25 -15
Other Financing Activities, net		 -10 -0.67 0.35 1.16 -5.97 4.43 3.06 0.87 4.65 -0.28 1.70
Cash Interest Paid		 0.65 0.06 0.07 0.08 1.16 0.09 0.10 0.11 0.12 0.13 0.14
Cash Income Taxes Paid		 14 8.80 0.00 - 18 17 0.64 39 16 17 1.84

Annual Balance Sheets for Catalyst Pharmaceuticals

This table presents Catalyst Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 60 42 85 60 112 192 238 376 470 851 1,104
Total Current Assets		 60 41 85 55 111 159 210 321 219 624 894
Cash & Equivalents		 28 14 57 17 90 130 171 298 138 518 709
Accounts Receivable		 - - - - 11 5.99 6.62 10 54 65 126
Inventories, net		 - - 0.00 0.06 1.96 4.65 7.87 6.81 16 20 37
Prepaid Expenses		 1.50 1.05 1.17 1.65 4.35 8.33 4.35 5.17 13 21 21
Plant, Property, & Equipment, net		 0.19 0.24 0.19 0.25 0.21 0.13 0.96 0.85 1.20 1.35 1.04
Total Noncurrent Assets		 0.01 0.01 0.01 5.02 0.80 33 27 54 250 226 209
Long-Term Investments		 - - 0.00 5.01 - - - 0.00 16 22 23
Intangible Assets		 - - - - - - 0.00 32 194 157 132
Noncurrent Deferred & Refundable Income Taxes		 - - - - 0.00 33 24 19 37 46 53
Other Noncurrent Operating Assets		 0.01 0.01 0.01 0.01 0.80 0.01 3.03 2.77 2.51 2.23 1.94
Total Liabilities & Shareholders' Equity		 60 42 85 60 112 192 238 376 470 851 1,104
Total Liabilities		 4.63 2.40 4.42 9.67 25 23 31 75 82 124 150
Total Current Liabilities		 3.44 2.09 4.27 9.51 24 23 27 58 76 121 147
Accounts Payable		 1.79 0.93 1.95 2.34 4.12 4.26 2.77 3.98 15 17 11
Accrued Expenses		 1.65 1.16 2.32 7.17 20 19 24 54 61 104 136
Total Noncurrent Liabilities		 1.18 0.30 0.16 0.15 0.65 0.00 3.89 18 6.17 3.10 2.56
Other Noncurrent Operating Liabilities		 1.18 0.30 0.16 0.15 0.65 0.00 3.89 18 6.17 3.10 2.56
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 55 39 81 51 88 170 207 300 388 728 954
Total Preferred & Common Equity		 55 39 81 51 88 170 207 300 388 728 954
Preferred Stock		 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 55 39 81 51 88 170 207 300 388 728 954
Common Stock		 146 147 208 211 216 223 233 251 267 442 480
Retained Earnings		 -90 -108 -127 -161 -129 -54 -26 50 121 285 474
Accumulated Other Comprehensive Income / (Loss)		 - - - -0.02 0.01 0.03 -0.15 0.02 0.01 0.06 0.00

Quarterly Balance Sheets for Catalyst Pharmaceuticals

This table presents Catalyst Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 333 407 444 413 647 706 772 909 972 1,052 1,148
Total Current Assets		 276 199 241 192 405 474 539 686 759 852 940
Cash & Equivalents		 256 148 179 121 310 376 442 581 653 690 756
Accounts Receivable		 9.34 33 43 48 60 57 58 71 66 106 131
Inventories, net		 7.13 10 11 9.04 20 18 20 20 19 28 35
Prepaid Expenses		 3.78 6.93 8.63 14 14 24 18 14 21 28 19
Plant, Property, & Equipment, net		 0.88 1.29 1.20 1.19 1.31 1.23 1.38 1.24 1.15 1.08 0.99
Total Noncurrent Assets		 56 207 202 220 241 231 232 222 212 198 206
Long-Term Investments		 - - - 13 15 13 15 24 21 19 27
Intangible Assets		 33 184 176 167 185 175 166 147 138 129 122
Noncurrent Deferred & Refundable Income Taxes		 20 20 23 37 38 40 48 48 51 48 55
Other Noncurrent Operating Assets		 2.84 2.71 2.64 2.58 2.44 2.37 2.30 2.16 2.08 2.01 1.86
Total Liabilities & Shareholders' Equity		 333 407 444 413 647 706 772 909 972 1,052 1,148
Total Liabilities		 63 74 69 65 85 98 111 115 116 131 135
Total Current Liabilities		 45 57 53 58 80 92 105 112 113 129 132
Accounts Payable		 2.53 3.39 4.42 4.60 10 7.12 12 11 5.53 9.10 7.15
Accrued Expenses		 42 53 48 53 69 85 94 100 107 120 125
Total Noncurrent Liabilities		 18 17 16 6.86 5.70 5.39 5.67 2.94 2.88 2.62 2.52
Other Noncurrent Operating Liabilities		 18 17 16 6.86 5.70 5.39 5.67 2.94 2.88 2.62 2.52
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 270 334 375 349 561 609 661 794 856 920 1,013
Total Preferred & Common Equity		 270 334 375 349 561 609 661 794 856 920 1,013
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 270 334 375 349 561 609 661 794 856 920 1,013
Common Stock		 246 254 258 262 417 423 432 452 462 473 489
Retained Earnings		 24 79 117 86 145 185 229 342 394 447 523
Accumulated Other Comprehensive Income / (Loss)		 0.03 0.01 0.02 0.02 0.00 0.00 0.00 -0.02 0.03 0.00 0.01

Annual Metrics And Ratios for Catalyst Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Catalyst Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 20,361.20% 16.39% 18.27% 52.10% 85.90% 23.49% 19.78%
EBITDA Growth		 -30.46% 10.74% -1.87% -84.93% 199.24% 24.55% 25.91% 100.45% 20.23% 99.41% 26.51%
EBIT Growth		 -30.46% 10.68% -1.88% -84.68% 198.25% 25.39% 25.73% 98.83% -9.75% 128.82% 31.10%
NOPAT Growth		 -39.80% 5.48% 3.11% -88.95% 222.89% 143.50% -46.88% 105.74% -18.81% 125.44% 31.79%
Net Income Growth		 -30.46% 10.68% -1.88% -84.68% 193.74% 135.24% -47.35% 110.42% -14.05% 129.50% 30.78%
EPS Growth		 -4.17% 12.00% 4.55% -57.14% 190.91% 136.67% -47.89% 102.70% -16.00% 107.94% 28.24%
Operating Cash Flow Growth		 -39.20% 0.29% 23.50% -90.27% 232.37% 30.11% 34.06% 92.22% 23.74% 67.00% -12.98%
Free Cash Flow Firm Growth		 -81.07% 0.47% 27.39% -80.26% 247.35% 27.68% 40.56% 77.90% -276.12% 216.24% -16.72%
Invested Capital Growth		 27.59% 62.44% -178.02% -152.69% 10.61% 525.62% -46.91% -86.98% 11,437.81% -19.35% 18.06%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 40.75% 0.75% 5.46% 11.71% 14.30% 6.79% 1.87%
EBITDA Q/Q Growth		 -13.02% 8.42% -7.17% -36.63% 219.71% -1.26% 10.18% 24.39% 21.14% 12.28% -0.68%
EBIT Q/Q Growth		 -12.98% 8.37% -7.12% -36.61% 218.06% 0.77% 8.42% 23.89% 16.95% 14.55% -0.80%
NOPAT Q/Q Growth		 -12.14% 8.87% -6.85% -35.94% 238.36% 81.69% -5.00% 21.81% 12.54% 12.37% -1.08%
Net Income Q/Q Growth		 -12.98% 8.37% -7.12% -36.61% 237.44% 4.91% -5.11% 24.15% 15.11% 14.77% -1.49%
EPS Q/Q Growth		 -8.70% 12.00% -5.00% -32.00% 233.33% 4.41% -5.13% 22.95% 18.87% 9.17% -2.33%
Operating Cash Flow Q/Q Growth		 -3.75% 1.21% 2.70% -19.80% 147.79% 1.84% 11.18% 21.97% 12.16% 6.78% -11.07%
Free Cash Flow Firm Q/Q Growth		 -0.96% -0.25% 6.54% -12.99% 197.29% 396.22% 12.85% 23.76% -16.65% 35.51% -15.17%
Invested Capital Q/Q Growth		 -26.27% 40.42% -40.06% -195.66% -92.90% -0.67% -34.79% -85.50% 8.89% -7.49% 5.39%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 100.00% 85.57% 85.69% 84.46% 83.94% 86.95% 86.00% 85.19%
EBITDA Margin		 0.00% 0.00% 0.00% -6,793.11% 32.95% 35.26% 37.53% 49.47% 31.99% 51.66% 54.57%
Operating Margin		 0.00% 0.00% 0.00% -7,059.03% 31.11% 34.69% 37.20% 47.54% 21.80% 39.68% 43.77%
EBIT Margin		 0.00% 0.00% 0.00% -6,800.70% 32.66% 35.18% 37.40% 48.89% 23.73% 43.98% 48.14%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -6,800.70% 31.16% 62.97% 28.03% 38.79% 17.93% 33.33% 36.39%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 95.41% 179.00% 74.97% 79.34% 75.56% 75.78% 75.60%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 4.59% -79.00% 25.03% 20.66% 24.44% 24.22% 24.40%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 659.19% 174.98% 918.58% 55.64% 70.04% 94.81%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 658.30% 174.86% 917.64% 53.07% 65.41% 91.75%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% -600.89% -154.01% -885.82% -34.89% -40.65% -69.32%
Return on Equity (ROE)		 -44.61% -38.13% -30.62% -51.62% 46.06% 58.30% 20.98% 32.76% 20.75% 29.38% 25.49%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 128.66% 236.27% 1,072.51% -140.92% 91.46% 78.25%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -46.63% 38.66% 27.49% 24.49% 34.14% 22.35% 32.73% 29.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -46.63% 36.89% 49.21% 18.36% 27.09% 16.89% 24.80% 21.92%
Return on Common Equity (ROCE)		 -44.61% -38.13% -30.62% -51.62% 46.06% 58.30% 20.98% 32.76% 20.75% 29.38% 25.49%
Return on Equity Simple (ROE_SIMPLE)		 -36.47% -45.98% -22.74% -66.96% 36.37% 44.21% 19.09% 27.65% 18.41% 22.52% 0.00%
Net Operating Profit after Tax (NOPAT)		 -14 -13 -13 -25 30 74 39 81 66 148 195
NOPAT Margin		 0.00% 0.00% 0.00% -4,941.32% 29.68% 62.09% 27.88% 37.72% 16.47% 30.07% 33.09%
Net Nonoperating Expense Percent (NNEP)		 -12.19% -9.26% -8.58% -13.05% 1.98% 0.90% 0.13% 0.93% 2.57% 4.62% 3.06%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 26.89% 16.91% 20.32% 20.42%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 14.43% 14.31% 15.54% 16.06% 13.05% 14.00% 14.81%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 3,175.19% 36.05% 37.15% 35.24% 26.65% 33.58% 36.15% 32.90%
R&D to Revenue		 0.00% 0.00% 0.00% 3,983.84% 18.42% 13.85% 12.03% 9.24% 23.39% 2.57% 2.16%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 7,159.03% 54.47% 51.00% 47.26% 36.40% 65.15% 46.32% 41.42%
Earnings before Interest and Taxes (EBIT)		 -20 -18 -18 -34 33 42 53 105 95 216 284
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -20 -18 -18 -34 34 42 53 106 127 254 321
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.66 2.21 4.12 3.88 4.41 2.04 3.38 6.44 4.62 3.42 3.01
Price to Tangible Book Value (P/TBV)		 3.66 2.21 4.12 3.88 4.41 2.04 3.38 7.22 9.25 4.36 3.49
Price to Revenue (P/Rev)		 0.00 0.00 0.00 394.52 3.78 2.91 4.96 9.04 4.50 5.06 4.87
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 12.12 4.62 17.68 23.30 25.10 15.19 13.39
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 8.25% 21.66% 5.66% 4.29% 3.98% 6.58% 7.47%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 7.02 32.56 808.16 7.01 10.34 9.60
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 277.54 2.85 1.73 3.60 7.64 4.11 3.97 3.63
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 8.66 4.90 9.59 15.45 12.86 7.68 6.65
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 8.74 4.92 9.62 15.64 17.33 9.02 7.54
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 9.61 2.79 12.91 20.27 24.97 13.19 10.97
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 8.43 4.57 8.40 14.11 11.41 8.13 10.24
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 9.88 5.46 9.56 17.36 0.00 10.10 13.29
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.08 -1.04 -1.03 -1.08 -1.11 -0.91 -0.88 -0.97 -0.66 -0.62 -0.76
Leverage Ratio		 1.15 1.07 1.06 1.11 1.25 1.18 1.14 1.21 1.23 1.18 1.16
Compound Leverage Factor		 1.15 1.07 1.06 1.11 1.25 1.18 1.14 1.21 1.23 1.18 1.16
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 24.24 17.84 43.55 7.58 10.59 10.93 15.62 17.96 15.31 14.66 14.29
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 17.41 19.79 19.97 5.80 4.62 7.00 7.76 5.57 2.88 5.17 6.08
Quick Ratio		 16.97 19.29 19.69 5.62 4.36 6.43 7.31 5.36 2.51 4.83 5.68
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -15 -15 -11 -20 30 38 53 94 -166 193 161
Operating Cash Flow to CapEx		 -76,774.86% -18,700.10% 0.00% -28,415.69% 182,168.42% 409,400.00% 5,913.03% 400,162.07% 62,164.50% 43,130.94% 359,775.86%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.01 1.18 0.78 0.65 0.70 0.94 0.74 0.60
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 14.41 22.34 25.11 12.45 8.27 6.14
Inventory Turnover		 0.00 0.00 0.00 0.00 14.67 5.16 3.50 4.69 4.63 3.91 3.08
Fixed Asset Turnover		 0.00 0.00 0.00 2.29 448.82 699.47 258.65 237.21 390.01 385.83 492.67
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 4.57 4.07 6.23 10.20 5.54 4.39 6.28
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 25.33 16.34 14.53 29.31 44.16 59.48
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 24.89 70.77 104.42 77.87 78.84 93.27 118.61
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 79.82 89.69 58.58 35.78 65.92 83.21 58.14
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 -54.93 6.41 62.18 56.62 42.23 54.23 119.95
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.92 -1.10 -3.05 -7.71 -6.89 29 16 2.03 234 189 223
Invested Capital Turnover		 0.00 0.00 0.00 -0.09 -14.02 10.62 6.28 24.35 3.38 2.33 2.87
Increase / (Decrease) in Invested Capital		 1.11 1.82 -1.95 -4.66 0.82 36 -14 -14 232 -45 34
Enterprise Value (EV)		 145 47 249 139 292 206 507 1,637 1,638 1,950 2,137
Market Capitalization		 203 87 333 197 386 346 698 1,936 1,792 2,489 2,869
Book Value per Share		 $0.67 $0.47 $0.95 $0.49 $0.85 $1.64 $2.01 $2.89 $3.64 $6.10 $7.76
Tangible Book Value per Share		 $0.67 $0.47 $0.95 $0.49 $0.85 $1.64 $2.01 $2.57 $1.82 $4.79 $6.69
Total Capital		 55 39 81 51 88 170 207 300 388 728 954
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -58 -40 -84 -58 -95 -140 -191 -298 -154 -539 -732
Capital Expenditures (CapEx)		 0.02 0.10 0.00 0.09 0.02 0.01 1.02 0.03 0.23 0.56 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.94 -1.05 -3.09 -7.81 -7.25 -3.79 -8.22 -35 5.63 -15 38
Debt-free Net Working Capital (DFNWC)		 56 39 81 46 87 136 183 263 143 503 747
Net Working Capital (NWC)		 56 39 81 46 87 136 183 263 143 503 747
Net Nonoperating Expense (NNE)		 5.95 4.58 5.34 9.30 -1.51 -1.05 -0.21 -2.29 -5.82 -16 -19
Net Nonoperating Obligations (NNO)		 -58 -40 -84 -58 -95 -140 -191 -298 -154 -539 -732
Total Depreciation and Amortization (D&A)		 0.03 0.04 0.05 0.04 0.30 0.09 0.19 1.24 33 38 38
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -1,561.11% -7.09% -3.18% -5.84% -16.42% 1.41% -2.97% 6.40%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 9,135.21% 85.30% 114.63% 129.97% 122.88% 35.98% 102.28% 126.81%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 9,135.21% 85.30% 114.63% 129.97% 122.88% 35.98% 102.28% 126.81%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.25) ($0.22) ($0.21) ($0.33) $0.31 $0.72 $0.38 $0.80 $0.67 $1.38 $1.75
Adjusted Weighted Average Basic Shares Outstanding		 82.88M 82.97M 102.56M 102.74M 102.94M 103.51M 103.38M 103.37M 106.28M 118.46M 122.29M
Adjusted Diluted Earnings per Share		 ($0.25) ($0.22) ($0.21) ($0.33) $0.30 $0.71 $0.37 $0.75 $0.63 $1.31 $1.68
Adjusted Weighted Average Diluted Shares Outstanding		 82.88M 82.97M 102.56M 102.74M 106.02M 106.24M 107.80M 111.38M 113.75M 124.94M 127.26M
Adjusted Basic & Diluted Earnings per Share		 ($0.25) ($0.22) ($0.21) ($0.33) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 80.86M 82.88M 85.80M 102.63M 103.41M 103.82M 102.74M 105.65M 117.86M 121.45M 122.12M
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -13 -13 -25 30 29 39 81 66 148 195
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -4,941.32% 29.68% 24.28% 27.88% 37.72% 16.47% 30.07% 33.09%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -6,800.70% 32.66% 35.18% 37.40% 48.89% 23.73% 43.98% 48.14%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 30.62% 8.31% 0.00% 0.18% 11.80%

Quarterly Metrics And Ratios for Catalyst Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Catalyst Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 122,123,884.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 122,123,884.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 0.52
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 79.39% 81.98% 15.40% 23.23% 25.33% 28.27% 43.56% 19.44% 15.31% 7.61% 5.63%
EBITDA Growth		 -210.89% 66.11% -12.28% 14.26% 326.31% 49.76% 109.63% 20.74% 20.70% -2.63% 16.42%
EBIT Growth		 -246.20% 41.50% -22.04% 15.00% 250.46% 58.82% 145.06% 24.21% 24.18% -3.07% 18.16%
NOPAT Growth		 -218.56% 30.86% -23.08% 9.12% 250.03% 52.36% 132.37% 25.69% 26.08% -4.34% 9.87%
Net Income Growth		 -235.24% 36.80% -21.28% 8.03% 242.65% 60.53% 143.77% 27.73% 20.28% -5.79% 12.33%
EPS Growth		 -245.00% 43.48% -26.92% 0.00% 220.69% 33.33% 136.84% 24.24% 20.00% -9.09% 11.11%
Operating Cash Flow Growth		 9.27% 38.85% 164.50% 108.54% 61.48% 27.37% 88.08% 11.17% -55.49% -36.66% -0.76%
Free Cash Flow Firm Growth		 -811.90% -637.77% 78.83% 111.65% 122.04% 146.17% 438.75% 438.61% -16.30% -87.82% -84.19%
Invested Capital Growth		 1,436.06% 11,437.81% 27.10% 11.89% -5.08% -19.35% -19.62% -17.24% 3.64% 18.06% 21.19%
Revenue Q/Q Growth		 3.12% 7.67% -10.91% 24.57% 4.88% 10.20% -0.28% 3.64% 1.25% 2.84% -2.11%
EBITDA Q/Q Growth		 -151.60% 289.62% -31.03% 69.33% 2.20% 25.48% -3.46% -2.47% 2.16% 1.23% 15.43%
EBIT Q/Q Growth		 -178.37% 222.85% -37.72% 91.78% 2.54% 29.68% -3.90% -2.80% 2.51% 1.22% 17.15%
NOPAT Q/Q Growth		 -171.61% 219.48% -30.22% 82.76% -1.54% 21.34% 6.43% -1.15% -1.23% -7.94% 22.25%
Net Income Q/Q Growth		 -181.47% 213.26% -33.20% 75.27% 7.57% 27.46% 1.43% -8.16% 1.30% -0.16% 20.94%
EPS Q/Q Growth		 -187.88% 213.79% -42.42% 73.68% 6.06% 25.71% 2.27% -8.89% 2.44% -4.76% 25.00%
Operating Cash Flow Q/Q Growth		 46.74% 23.31% -42.63% 100.89% 13.62% -2.74% -15.29% 18.74% -54.50% 38.39% 32.74%
Free Cash Flow Firm Q/Q Growth		 -62.13% 11.51% 85.78% 157.10% 206.65% 85.38% 4.37% -9.21% -52.35% -73.02% 35.43%
Invested Capital Q/Q Growth		 9.25% 8.89% 0.81% -6.69% -7.33% -7.49% 0.48% -3.93% 16.05% 5.39% 3.14%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 86.20% 85.70% 87.29% 87.45% 85.02% 84.74% 87.34% 85.94% 84.73% 82.92% 90.31%
EBITDA Margin		 -28.68% 50.51% 39.10% 53.15% 51.79% 58.98% 57.10% 53.73% 54.22% 53.36% 62.92%
Operating Margin		 -36.21% 37.71% 27.54% 44.21% 39.56% 44.31% 44.81% 45.24% 44.66% 40.52% 49.02%
EBIT Margin		 -37.03% 42.24% 29.53% 45.46% 44.45% 52.31% 50.41% 47.28% 47.87% 47.11% 56.38%
Profit (Net Income) Margin		 -29.96% 31.51% 23.63% 33.24% 34.10% 39.44% 40.12% 35.55% 35.57% 34.53% 42.66%
Tax Burden Percent		 80.91% 74.60% 80.01% 73.12% 76.71% 75.40% 79.59% 75.20% 74.31% 73.29% 75.67%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 25.40% 19.99% 26.88% 23.29% 24.60% 20.41% 24.80% 25.69% 26.71% 24.33%
Return on Invested Capital (ROIC)		 -77.25% 95.02% 43.05% 67.46% 66.79% 77.82% 89.71% 94.55% 92.47% 85.11% 105.70%
ROIC Less NNEP Spread (ROIC-NNEP)		 -74.82% 93.36% 42.39% 67.06% 65.15% 75.35% 88.36% 94.13% 91.87% 83.95% 104.50%
Return on Net Nonoperating Assets (RNNOA)		 47.17% -61.38% -22.45% -38.68% -38.15% -46.83% -60.65% -68.30% -67.76% -63.43% -80.27%
Return on Equity (ROE)		 -30.08% 33.64% 20.60% 28.78% 28.64% 30.99% 29.06% 26.25% 24.72% 21.68% 25.43%
Cash Return on Invested Capital (CROIC)		 -124.57% -140.92% 4.21% 18.82% 68.11% 91.46% 104.88% 111.82% 91.37% 78.25% 76.22%
Operating Return on Assets (OROA)		 -34.57% 39.78% 23.05% 34.34% 34.54% 38.93% 34.65% 31.47% 30.36% 28.38% 32.73%
Return on Assets (ROA)		 -27.97% 29.68% 18.44% 25.11% 26.50% 29.35% 27.58% 23.66% 22.56% 20.80% 24.77%
Return on Common Equity (ROCE)		 -30.08% 33.64% 20.60% 28.78% 28.64% 30.99% 29.06% 26.25% 24.72% 21.68% 25.43%
Return on Equity Simple (ROE_SIMPLE)		 17.80% 0.00% 11.60% 11.20% 21.61% 0.00% 24.85% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -26 31 22 40 39 47 50 50 49 45 55
NOPAT Margin		 -25.35% 28.13% 22.03% 32.33% 30.35% 33.41% 35.66% 34.02% 33.18% 29.70% 37.09%
Net Nonoperating Expense Percent (NNEP)		 -2.43% 1.65% 0.66% 0.40% 1.63% 2.47% 1.35% 0.42% 0.61% 1.16% 1.20%
Return On Investment Capital (ROIC_SIMPLE)		 - 8.02% - - - 6.51% 6.35% 5.82% 5.35% 4.75% 5.47%
Cost of Revenue to Revenue		 13.80% 14.30% 12.71% 12.55% 14.98% 15.26% 12.67% 14.06% 15.27% 17.09% 9.69%
SG&A Expenses to Revenue		 32.68% 38.02% 47.65% 33.19% 35.65% 31.16% 33.17% 31.35% 31.99% 35.00% 33.01%
R&D to Revenue		 81.47% 1.78% 2.62% 2.43% 2.55% 2.68% 2.75% 2.97% 1.79% 1.18% 1.78%
Operating Expenses to Revenue		 122.42% 47.99% 59.75% 43.24% 45.46% 40.43% 42.53% 40.70% 40.08% 42.39% 41.29%
Earnings before Interest and Taxes (EBIT)		 -38 47 29 56 57 74 71 69 71 72 84
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -29 56 39 65 67 84 81 79 80 81 94
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.57 4.62 3.03 3.01 3.57 3.42 3.71 3.09 2.62 3.01 2.99
Price to Tangible Book Value (P/TBV)		 6.87 9.25 4.51 4.22 4.77 4.36 4.55 3.69 3.05 3.49 3.39
Price to Revenue (P/Rev)		 3.58 4.50 4.13 4.21 5.12 5.06 5.51 4.74 4.17 4.87 5.07
Price to Earnings (P/E)		 20.08 25.10 26.10 26.85 16.52 15.19 14.92 12.68 11.08 13.39 13.66
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 4.98% 3.98% 3.83% 3.72% 6.05% 6.58% 6.70% 7.88% 9.02% 7.47% 7.32%
Enterprise Value to Invested Capital (EV/IC)		 5.18 7.01 5.83 6.55 9.34 10.34 12.36 10.84 8.06 9.60 9.76
Enterprise Value to Revenue (EV/Rev)		 3.19 4.11 3.34 3.32 4.13 3.97 4.38 3.53 2.94 3.63 3.75
Enterprise Value to EBITDA (EV/EBITDA)		 10.57 12.86 11.26 11.07 8.41 7.68 7.90 6.37 5.26 6.65 6.70
Enterprise Value to EBIT (EV/EBIT)		 13.76 17.33 15.92 15.40 10.08 9.02 9.05 7.25 5.96 7.54 7.56
Enterprise Value to NOPAT (EV/NOPAT)		 19.08 24.97 23.24 23.03 14.46 13.19 13.25 10.56 8.64 10.97 11.21
Enterprise Value to Operating Cash Flow (EV/OCF)		 8.69 11.41 8.40 7.32 8.47 8.13 8.73 7.17 7.25 10.24 10.76
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 154.87 36.78 13.35 10.10 10.50 8.78 8.98 13.29 14.03
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.63 -0.66 -0.53 -0.58 -0.59 -0.62 -0.69 -0.73 -0.74 -0.76 -0.77
Leverage Ratio		 1.21 1.23 1.18 1.17 1.17 1.18 1.15 1.15 1.15 1.16 1.14
Compound Leverage Factor		 1.21 1.23 1.18 1.17 1.17 1.18 1.15 1.15 1.15 1.16 1.14
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 12.78 14.98 13.66 13.13 14.68 14.11 17.55 15.88 13.21 13.66 15.69
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.32 2.88 5.09 5.14 5.11 5.17 6.14 6.71 6.62 6.08 7.10
Quick Ratio		 2.92 2.51 4.66 4.69 4.75 4.83 5.84 6.36 6.19 5.68 6.70
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -227 -201 -29 16 50 93 97 88 42 11 15
Operating Cash Flow to CapEx		 70,512.50% 59,836.56% 16,042.71% 641,350.00% 28,135.52% 80,542.05% 0.00% 274,223.08% 0.00% 140,284.38% 220,692.59%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.93 0.94 0.78 0.76 0.78 0.74 0.69 0.67 0.63 0.60 0.58
Accounts Receivable Turnover		 12.14 12.45 8.76 8.69 8.66 8.27 8.12 9.08 7.02 6.14 5.91
Inventory Turnover		 5.86 4.63 3.60 4.03 4.34 3.91 3.74 4.33 3.45 3.08 3.06
Fixed Asset Turnover		 336.94 390.01 317.28 357.59 358.91 385.83 419.82 470.12 470.65 492.67 534.67
Accounts Payable Turnover		 13.29 5.54 7.99 10.04 7.80 4.39 6.92 12.57 8.02 6.28 9.14
Days Sales Outstanding (DSO)		 30.06 29.31 41.66 41.99 42.14 44.16 44.98 40.20 51.98 59.48 61.79
Days Inventory Outstanding (DIO)		 62.31 78.84 101.32 90.67 84.14 93.27 97.67 84.22 105.87 118.61 119.12
Days Payable Outstanding (DPO)		 27.47 65.92 45.68 36.36 46.81 83.21 52.75 29.05 45.52 58.14 39.95
Cash Conversion Cycle (CCC)		 64.90 42.23 97.30 96.29 79.47 54.23 89.90 95.38 112.33 119.95 140.95
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 215 234 236 220 204 189 189 182 211 223 230
Invested Capital Turnover		 3.05 3.38 1.95 2.09 2.20 2.33 2.52 2.78 2.79 2.87 2.85
Increase / (Decrease) in Invested Capital		 201 232 50 23 -11 -45 -46 -38 7.42 34 40
Enterprise Value (EV)		 1,112 1,638 1,374 1,441 1,902 1,950 2,340 1,973 1,702 2,137 2,241
Market Capitalization		 1,246 1,792 1,699 1,830 2,360 2,489 2,945 2,647 2,411 2,869 3,024
Book Value per Share		 $3.27 $3.64 $4.81 $5.15 $5.57 $6.10 $6.54 $7.02 $7.52 $7.76 $8.29
Tangible Book Value per Share		 $1.70 $1.82 $3.23 $3.67 $4.17 $4.79 $5.33 $5.89 $6.47 $6.69 $7.29
Total Capital		 349 388 561 609 661 728 794 856 920 954 1,013
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -134 -154 -326 -389 -457 -539 -605 -674 -709 -732 -783
Capital Expenditures (CapEx)		 0.06 0.09 0.20 0.01 0.26 0.09 0.00 0.03 0.00 0.03 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 13 5.63 15 6.42 -8.73 -15 -6.59 -7.07 34 38 52
Debt-free Net Working Capital (DFNWC)		 134 143 325 382 434 503 574 646 724 747 808
Net Working Capital (NWC)		 134 143 325 382 434 503 574 646 724 747 808
Net Nonoperating Expense (NNE)		 4.73 -3.74 -1.57 -1.13 -4.83 -8.55 -6.30 -2.25 -3.54 -7.37 -8.32
Net Nonoperating Obligations (NNO)		 -134 -154 -326 -389 -457 -539 -605 -674 -709 -732 -783
Total Depreciation and Amortization (D&A)		 8.57 9.14 9.43 9.44 9.45 9.46 9.46 9.46 9.42 9.54 9.77
Debt-free, Cash-free Net Working Capital to Revenue		 3.80% 1.41% 3.56% 1.48% -1.90% -2.97% -1.23% -1.27% 5.85% 6.40% 8.73%
Debt-free Net Working Capital to Revenue		 38.52% 35.98% 79.02% 87.95% 94.16% 102.28% 107.37% 115.62% 125.17% 126.81% 135.35%
Net Working Capital to Revenue		 38.52% 35.98% 79.02% 87.95% 94.16% 102.28% 107.37% 115.62% 125.17% 126.81% 135.35%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.29) $0.32 $0.20 $0.35 $0.37 $0.46 $0.47 $0.43 $0.43 $0.42 $0.52
Adjusted Weighted Average Basic Shares Outstanding		 106.57M 106.28M 116.81M 118.18M 118.93M 118.46M 121.47M 122.16M 122.60M 122.29M 122.25M
Adjusted Diluted Earnings per Share		 ($0.29) $0.33 $0.19 $0.33 $0.35 $0.44 $0.45 $0.41 $0.42 $0.40 $0.50
Adjusted Weighted Average Diluted Shares Outstanding		 106.57M 113.75M 123.40M 124.66M 125.41M 124.94M 126.96M 127.54M 127.09M 127.26M 126.90M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 106.61M 117.86M 118.12M 118.69M 119.27M 121.45M 121.98M 122.39M 122.91M 122.12M 122.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -26 31 22 40 39 47 50 50 49 45 55
Normalized NOPAT Margin		 -25.35% 28.13% 22.03% 32.33% 30.35% 33.41% 35.66% 34.02% 33.18% 29.70% 37.09%
Pre Tax Income Margin		 -37.03% 42.24% 29.53% 45.46% 44.45% 52.31% 50.41% 47.28% 47.87% 47.11% 56.38%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.45% 0.43% 0.21% 0.18% 0.00% 0.00% 0.00% 11.80% 18.02%

Financials Breakdown Chart

Key Financial Trends

Here are the key trends for Catalyst Pharmaceuticals (NASDAQ: CPRX) drawn from the last four years of quarterly statements. The focus is on notable movements in revenue, profitability, liquidity, and capital allocation.

  • Strong revenue growth and margin stability: Operating revenue rose from about $60.8 million in 2022 Q4 to $152.6 million in 2025 Q4, with gross margin consistently in the mid-to-high 80s% (roughly 83–85%).
  • Net income growth over the period: Net income attributable to common shareholders increased from roughly $25.5 million in 2022 Q4 to about $52.7 million in 2025 Q4, indicating meaningful earnings expansion alongside revenue gains.
  • Solid cash position and liquidity: Cash & equivalents climbed from around $256 million (2022 Q3) to approximately $690 million (2025 Q3), providing substantial liquidity to fund operations, capex (where applicable), and potential strategic moves.
  • Healthy operating cash flow: Net cash from continuing operating activities was consistently positive in 2025, with quarterly figures around $60–$72 million in early 2025 and $32–$45 million in later quarters, underscoring strong cash generation from core operations.
  • Very strong balance sheet and solvency: Total equity consistently sits well above total liabilities (e.g., ~\$794–\$920 million in 2025 across quarters), and current assets dramatically exceed current liabilities, yielding a robust liquidity cushion (current ratio well above 4x, often around 6–7x in recent quarters).
  • Capital return activity: Repurchase of common equity occurred in 2025 Q4 (approximately \$25.3 million), signaling management’s willingness to return capital to shareholders and potentially support valuation.
  • R&D intensity improving relative to revenue: Research & Development expense declined as a percentage of revenue in 2025 versus prior years (e.g., 1–2% of revenue in 2025 vs higher in earlier years), suggesting improved efficiency in the company’s R&D spend.
  • Past restatements and quarterly volatility: The company has noted restatements in earlier periods (e.g., 2023 Q4 restated and 2024 Q1 restated). While the current data reflects a cleaned-up baseline, investors should consider historical revisions when evaluating trend reliability.
  • Expense mix pressures on margins: Selling, General & Administrative (SG&A) expense rose in absolute terms relative to revenue (SG&A around 35% of revenue in 2025 Q4 vs roughly 31% in 2024 Q4), which can compress margin even as revenue grows.
  • Earnings per share show some quarterly volatility: Diluted earnings per share in 2025 Q4 (~$0.40) is slightly below the prior-year quarter (2024 Q4 around $0.44), despite stronger top-line growth. This indicates near-term EPS pressure or mix effects even as net income expands.
  • Quarterly variability in quarterly profitability: While trailing four-quarter trends are positive, quarterly pushes and pulls (e.g., lower Q3 2025 EPS vs Q4 2024) suggest near-term earnings volatility that investors may want to monitor as the pipeline and product mix evolve.
05/25/26 07:27 PM ETAI Generated. May Contain Errors.

Catalyst Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Catalyst Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Catalyst Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $214.33 million in 2025, falling from -$20.23 million in 2015. The previous period was $163.89 million in 2024. View Catalyst Pharmaceuticals' forecast to see where analysts expect Catalyst Pharmaceuticals to go next.

Catalyst Pharmaceuticals' total operating income in 2025 was $257.78 million, based on the following breakdown:
  • Total Gross Profit: $501.74 million
  • Total Operating Expenses: $243.96 million

Over the last 10 years, Catalyst Pharmaceuticals' total revenue changed from $0.00 in 2015 to $588.99 million in 2025, a change of 58,898,900,000.0%.

Catalyst Pharmaceuticals' total liabilities were at $149.71 million at the end of 2025, a 21.0% increase from 2024, and a 3,136.8% increase since 2015.

In the past 10 years, Catalyst Pharmaceuticals' cash and equivalents has ranged from $13.89 million in 2016 to $709.17 million in 2025, and is currently $709.17 million as of their latest financial filing in 2025.

Over the last 10 years, Catalyst Pharmaceuticals' book value per share changed from 0.67 in 2015 to 7.76 in 2025, a change of 1,059.1%.


Related Companies

Financial statements for NASDAQ:CPRX last updated on 5/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel